Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$8.93 USD
-0.24 (-2.62%)
Updated May 14, 2024 04:00 PM ET
After-Market: $8.93 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
ADVM 8.93 -0.24(-2.62%)
Will ADVM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ADVM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ADVM
Down -19.72% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM)
Are Medical Stocks Lagging Ligand Pharmaceuticals (LGND) This Year?
ADVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Absci (ABSI) to Report Q1 Earnings: Here's What to Expect
PetIQ (PETQ) Gears Up to Report Q1 Earnings: What's in Store?
Recursion (RXRX) to Report Q1 Earnings: What's in the Cards?
Other News for ADVM
Buy Rating Affirmed for Adverum’s Gene Therapy on Promising Interim Phase 2 Results and Potential Standard of Care Shift in nAMD Treatment
Adverum Biotechnologies (ADVM) Receives a New Rating from RBC Capital
Adverum Biotechnologies Reports Q1 2024 Results: A Detailed Look at Financials and Pipeline Progress
Adverum Biotechnologies: Q1 Earnings Snapshot
Adverum Biotechnologies Reports First Quarter 2024 Financial Results and Provides Pipeline Highlights